Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Kyriacos Mitrophanous, Jean Marc Gurruchaga et al.|The Lancet|2014Cited by 436
Trial of Lixisenatide in Early Parkinson’s DiseaseWassilios G. Meissner, Olivier Rascol, Pascal Derkinderen et al.|New England Journal of Medicine|2024Cited by 302